{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:50:49Z","timestamp":1755600649755},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,26]]},"DOI":"10.7759\/cureus.15260","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T18:12:08Z","timestamp":1622052728000},"source":"Crossref","is-referenced-by-count":1,"title":["Steroid-Resistant Double-Seronegative Optic Neuritis Responds Favorably to Plasma Exchange"],"prefix":"10.7759","author":[{"given":"Matthew C","family":"Mason","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario A","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Kesserwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(13)70259-x","article-title":"Optic neuritis","volume":"13","author":"Toosy AT","year":"2014","unstructured":"Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014, 13:83-99. 10.1016\/s1474-4422(13)70259-x","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2019.06.001","article-title":"Critical review: typical and atypical optic neuritis","volume":"64","author":"Abel A","year":"2019","unstructured":"Abel A, McClelland C, Lee MS. Critical review: typical and atypical optic neuritis. Surv Ophthalmol. 2019, 64:770-9. 10.1016\/j.survophthal.2019.06.001","journal-title":"Surv Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.07.014","article-title":"Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies","volume":"220","author":"Hassan MB","year":"2020","unstructured":"Hassan MB, Stern C, Flanagan EP, et al.. Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol. 2020, 220:110-4. 10.1016\/j.ajo.2020.07.014","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000700","article-title":"Acute management of optic neuritis: an evolving paradigm","volume":"38","author":"Horton L","year":"2018","unstructured":"Horton L, Bennett JL. Acute management of optic neuritis: an evolving paradigm. J Neuroophthalmol. 2018, 38:358-67. 10.1097\/WNO.0000000000000700","journal-title":"J Neuroophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101206010065","article-title":"Optic neuritis, its differential diagnosis and management","volume":"6","author":"Hoorbakht H","year":"2012","unstructured":"Hoorbakht H, Bagherkashi F. Optic neuritis, its differential diagnosis and management. Open Ophthalmol J. 2012, 6:65-72. 10.2174\/1874364101206010065","journal-title":"Open Ophthalmol J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin MH","year":"2013","unstructured":"Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res. 2013, 36:159-71. 10.1016\/j.preteyeres.2013.03.001","journal-title":"Prog Retin Eye Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody\u00a0disease","volume":"266","author":"Wynford-Thomas R","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody\u00a0disease. J Neurol. 2019, 266:1280-6. 10.1007\/s00415-018-9122-2","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen JJ","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, et al.. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018, 195:8-15. 10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius S","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, et al.. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016, 13:280. 10.1186\/s12974-016-0718-0","journal-title":"J Neuroinflammation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey D","year":"2019","unstructured":"Dubey D, Pittock SJ, Krecke KN, et al.. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019, 76:301-9. 10.1001\/jamaneurol.2018.4053","journal-title":"JAMA Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.4.382","article-title":"Clinical, CSF, and MRI findings in Devic's neuromyelitis optica","volume":"60","author":"O'Riordan JI","year":"1996","unstructured":"O'Riordan JI, Gallagher HL, Thompson AJ, et al.. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996, 60:382-7. 10.1136\/jnnp.60.4.382","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.26","article-title":"Clinical course of optic neuritis in patients with relapsing neuromyelitis optica","volume":"126","author":"Papais-Alvarenga RM","year":"2008","unstructured":"Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008, 126:12-6. 10.1001\/archophthalmol.2007.26","journal-title":"Arch Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.3502","article-title":"Trends in optic neuritis incidence and prevalence in the UK and association with systemic and neurologic disease","volume":"77","author":"Braithwaite T","year":"2020","unstructured":"Braithwaite T, Subramanian A, Petzold A, et al.. Trends in optic neuritis incidence and prevalence in the UK and association with systemic and neurologic disease. JAMA Neurol. 2020, 77:1514-23. 10.1001\/jamaneurol.2020.3502","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa H","year":"2019","unstructured":"Ishikawa H, Kezuka T, Shikishima K, et al.. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019, 126:1385-98. 10.1016\/j.ophtha.2019.04.042","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck RW","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, et al.. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992, 326:581-8. 10.1056\/NEJM199202273260901","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090060061023","article-title":"Optic neuritis treatment trial. One-year follow-up results","volume":"111","author":"Beck RW","year":"1993","unstructured":"Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993, 111:773-5. 10.1001\/archopht.1993.01090060061023","journal-title":"Arch Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle H","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S, et al.. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012, 130:858-62. 10.1001\/archophthalmol.2012.1126","journal-title":"Arch Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2011.01612.x","article-title":"Treatment of steroid-unresponsive optic neuritis with plasma exchange","volume":"126","author":"Roesner S","year":"2012","unstructured":"Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012, 126:103-8. 10.1111\/j.1600-0404.2011.01612.x","journal-title":"Acta Neurol Scand"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/59330-steroid-resistant-double-seronegative-optic-neuritis-responds-favorably-to-plasma-exchange","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:24Z","timestamp":1707506964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/59330-steroid-resistant-double-seronegative-optic-neuritis-responds-favorably-to-plasma-exchange"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.15260","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}